| Drug Name: | Enoxacin (74011-58-8) |
|---|---|
| PubChem ID: | 3229 |
| SMILES: | CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O |
| InchiKey: | IDYZIJYBMGIQMJ-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Antineoplastic Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Nucleic Acid Synthesis Inhibitors, Topoisomerase II Inhibitors, Topoisomerase Inhibitors |
| Molecular Weight (dalton) | : | 320.324 |
| LogP | : | 0.6633 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 87.46 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Fenbufen (36330-85-5) | Convulsions | Antagonistic | Not fully understood Experiments in mice have shown that quinolones competitively inhibit the binding of gamma-amino butyric acid (GABA) to its receptors Enoxacin and fenbufen are known to affect the GABA receptor site in the hippocampus and frontal cortex of mice, which is associated with convulsive activity the NSAID simply lowers the amount of quinolone needed to precipitate convulsions in already susceptible individuals | A case of convulsion, loss of consciousness and subsequent acute renal failure caused by enoxacin and fenbufen |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category